← Back to search

ZETEO TECH, INC.

SYKESVILLE, MD, 21784

Unclaimed

Source Records

No company-reported description yet. Owners can add one after claiming the profile.

Capabilities

Prime contracting experience

14 records from government sources. Past participation is not evidence of current teaming interest.

RoleAgencyDescriptionVehicleObligatedAction datePeriod
Prime
National Aeronautics and Space Administration
National Aeronautics and Space Administration
PHASE II - MINIATURE TOF MASS SPECTROMETER WITH ENHANCED RESOLUTION—$1,274,213Sep 15, 2026Jun 11, 2024 – Sep 30, 2027
Prime
Department of Homeland Security
Office of Procurement Operations
OPEN BROAD AGENCY ANNOUNCEMENT 70RDND19R00000003, TOPIC SOLICITATION NO. 15 70RWMD23R00000007 AGENT-AGNOSTIC BIODETECTION SYSTEM FFP CONTRACT AWARD FOR RESEARCH AND DEVELOPMENT SERVICES TO ZETEO TECH INC.—$5,247,419Sep 1, 2026Sep 29, 2023 – Apr 30, 2027
Prime
Department of Defense
Department of the Air Force
AEROSOL CHEMICAL AND BIOLOGICAL THREAT DETECTION AND IDENTIFICATION FOR CRITICAL INFRASTRUCTURE—$1,249,174Jun 29, 2026Aug 26, 2025 – Mar 1, 2027
Prime
Department of Defense
Department of the Army
DESIGN A COMPACT MODULAR AEROSOL SAMPLER MICROSENSOR AND DELIVER 20 PROTOTYPES FOR TEST AND EVALUATION.—$1,314,886May 7, 2026Jun 9, 2025 – Jun 8, 2027
Prime
Department of Defense
Department of the Army
FIRST MONTHLY TECHNICAL REPORT—$996,920Aug 15, 2025Jul 26, 2019 – Jul 31, 2024
Prime
Department of Homeland Security
Office of Procurement Operations
PHASE III SBIR CONTRACT—$1,869,180Jun 30, 2025Sep 27, 2023 – Sep 26, 2024
Prime
Department of Homeland Security
Office of Procurement Operations
SBIR PHASE II AWARD ZETEO TECH.—$1,200,000May 5, 2025May 23, 2024 – Dec 28, 2025
Prime
Department of Homeland Security
Office of Procurement Operations
CWMD OBAA AWARD TO ZETEO TECH, INC. FOR TS 9 RESEARCH AND DEVELOPMENT.—$2,000,248Nov 1, 2024Aug 12, 2022 – Mar 10, 2025
Prime
Department of Homeland Security
Office of Procurement Operations
IGF::CL,CT::IGF RESEARCH AND DEVELOPMENT SERVICES FOR THE DEPARTMENT OF HOMELAND SECURITY, SCIENCE AND TECHNOLOGY DIRECTORATE, CHEMICAL AND BIOLOGICAL DEFENSE DIVISION FOR THE DETECTION OF BIOLOGICAL THREAT AGENTS VIA TRIGGERED MASS SPECTROMETRY.—$7,894,514Jun 25, 2024Aug 30, 2018 – Aug 30, 2023
Prime
Department of Transportation
Immediate Office of the Secretary of Transportation
SBIR PHASE II AWARD TO ZETEO TECH, INC. UNDER TOPIC 20-NH1.—$499,650May 29, 2024Apr 22, 2021 – Apr 21, 2023
Prime
Department of Defense
Department of the Army
SBIR PHASE 2 CONTRACT "FIELD PORTABLE BIOAEROSOL IDENTIFICATION WITH MINIATURIZED MALDI TOF MS"—$1,098,511Mar 26, 2024Mar 15, 2023 – Mar 31, 2025
Prime
Department of Homeland Security
Office of Procurement Operations
SBIR PHASE II 21.1-DHS211-011-0023-II—$995,763Mar 29, 2023Apr 6, 2022 – Apr 5, 2024
Prime
Department of Defense
Department of the Army
AWARD OF ZETEO'S ARMY SBIR PHASE II ENHANCEMENT MEDICAL R&D CONTRACT FOR "MILITARY WORKING DOG HEARING PROTECTION/ACTIVE COMMUNICATION SYSTEM"—$549,999Apr 20, 2022Feb 1, 2021 – Sep 30, 2022
Prime
Department of Defense
Department of the Army
IGF::OT::IGF STTR PHASE II AWARD—$5,688,960Mar 2, 2022Aug 23, 2017 – Aug 3, 2022

Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.

Subcontracting experience

2 records from government sources. Past participation is not evidence of current teaming interest.

RoleAgencyDescriptionVehicleObligatedAction datePeriod
Subcontractor
Department of Health and Human Services
THE PROPOSED RESEARCH FOCUSES ON EVALUATING A NONINVASIVE DIAGNOSTIC PLATFORM THAT USES EXHALED BREATH TO DIAGNOSE LOWER RESPIRATORY TRACT INFECTIONS (LRTIS) IN HIGH-RISK POPULATIONS WITHIN CRITICAL CARE ENVIRONMENTS, INCLUDING INTUBATED PATIENTS WITH MECHANICAL VENTILATION AND NON-INTUBATED INPATIENTS. THIS PLATFORM MEASURES HOST PROTEASE ACTIVITY, SPECIFICALLY NEUTROPHIL ELASTASE (HNE), MATRIX METALLOPROTEINASES (MMPS), AND CATHEPSINS, AS HOST IMMUNE RESPONSES TO DISTINGUISH BETWEEN RESPIRATORY COLONIZATION AND ACTIVE INFECTION, AS WELL AS DIFFERENTIATE BACTERIAL FROM VIRAL INFECTIONS. ADDITIONALLY, THE PLATFORM INCORPORATES THE MEASUREMENT OF SS-LACTAMASE ACTIVITY TO EVALUATE BACTERIAL RESISTANCE TO GUIDE ANTIBIOTIC SUSCEPTIBILITY ASSESSMENTS. THIS DIAGNOSTIC STRATEGY INTRODUCES TWO KEY INNOVATIONS. FIRST, THE EXHALED BREATH SAMPLING SYSTEM OFFERS HIGH EFFICIENCY IN CAPTURING PROTEIN MATERIALS FROM THE LOWER RESPIRATORY TRACT AND CAN BE FEASIBLY INTEGRATED INTO EXISTING CLINICAL WORKFLOWS IN INTENSIVE CARE SETTINGS. SECOND, THE PLATFORM INCLUDES A COST-EFFECTIVE AND RAPID MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS SPECTROMETRY (MALDI-MS) ASSAY THAT EMPLOYS CUSTOMIZED HIGH-SPECIFICITY SENSOR MOLECULES ALLOWING THE DETECTION OF MULTIPLE TARGETS IN A MULTIPLEXED FASHION, INCLUDING BOTH HOST PROTEASES AND BACTERIAL SS-LACTAMASES. THE INFORMATION PROVIDED BY THIS DIAGNOSTIC PLATFORM IS DIRECTLY RELEVANT TO CRITICAL CLINICAL DECISION-MAKING. SPECIFICALLY, SENSITIVE AND SPECIFIC QUANTIFICATION OF HOST PROTEASE ACTIVITY ALLOWS FOR THE DIFFERENTIATION OF BACTERIAL COLONIZATION FROM ACTIVE BACTERIAL OR VIRAL INFECTION, WHICH ENABLES CLINICIANS TO IDENTIFY PATIENTS WHO TRULY REQUIRE ANTIBIOTIC THERAPY. IN PARALLEL, FUNCTIONAL ANALYSIS OF SS-LACTAMASE ACTIVITY WITHIN THE SAME SAMPLE ALLOWS THE DIFFERENTIATION AMONG MAJOR CLASSES OF RESISTANCE ENZYMES, BROAD-SPECTRUM SS-LACTAMASES (BSBL), EXTENDED-SPECTRUM SS-LACTAMASES (ESBL), AMPC SS-LACTAMASES, AND CARBAPENEMASES, THUS SUPPORTING PRECISE AND TARGETED ANTIMICROBIAL INTERVENTIONS. THIS APPROACH OFFERS SIGNIFICANT ADVANTAGES OVER CONVENTIONAL DIAGNOSTIC METHODS, WHICH OFTEN RELY ON BRONCHOALVEOLAR LAVAGE (BAL) AND MICROBIAL CULTURE WHICH ARE INVASIVE AND TYPICALLY REQUIRE SEVERAL DAYS TO DELIVER RESULTS. SIMILARLY, CURRENT CULTURE-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) SUFFERS FROM DELAYS AND LIMITED SENSITIVITY, WHILE GENOMIC METHODS SUCH AS POLYMERASE CHAIN REACTION (PCR) AND WHOLE GENOME SEQUENCING (WGS) MAY INCUR HIGH COSTS AND MAY NOT RELIABLY DETECT EMERGING OR UNKNOWN RESISTANCE MECHANISMS NOR CAN THESE METHODS RELIABLY DISTINGUISH BETWEEN COLONIZATION AND INFECTION. THE PROPOSED WORK HAS THE POTENTIAL TO SUBSTANTIALLY ADVANCE LRTI MANAGEMENT IN CRITICAL CARE SETTINGS, INCLUDING REDUCING UNNECESSARY ANTIBIOTIC USE, ENABLING EARLIER AND MORE EFFECTIVE TREATMENT OF INFECTIONS CAUSED BY ANTIBIOTIC-RESISTANT BACTERIA, AND ULTIMATELY IMPROVING PATIENT OUTCOMES. BEYOND THIS STUDY, BREATHBIOMICS™ WILL OFFER A NONINVASIVE ALTERNATIVE TO BAL OR SPUTUM COLLECTION FOR RESPIRATORY INFECTION DIAGNOSIS IN CHILDREN AND OTHER PATIENT POPULATIONS WHICH WOULD BENEFIT FROM NON-INVASIVE SAMPLING OF THE LOWER AIRWAYS.
KC4100
Parent award context
Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response
Parent award NAICS: 541714
Parent award performance state: MA
Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA
View parent award on USAspending
—$247,988Aug 19, 2025— – —
Subcontractor
Department of Defense
USER SOFTWARE
176638
Parent award context
Parent award agency: Department of Defense · Department of the Navy
Parent award NAICS: 541712
Parent award performance state: MD
Parent award description: SUPPORT TO JPEO RESEARCH, DEVELOPMENT, AND SYSTEMS ENGINEERING
View parent award on USAspending
N0002413D6400USAspending$156,872Jun 23, 2022— – —

Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.

Agencies supported

  • Department of Homeland SecurityGov-sourced
  • National Aeronautics and Space AdministrationGov-sourced
  • Department of DefenseGov-sourced
  • Department of TransportationGov-sourced
ZETEO TECH, INC. — Federal Contractor Profile | FedSub